351 related articles for article (PubMed ID: 30700265)
21. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.
Baquero MT; Lostritto K; Gustavson MD; Bassi KA; Appia F; Camp RL; Molinaro AM; Harris LN; Rimm DL
Breast Cancer Res; 2011 Nov; 13(5):R85. PubMed ID: 21888627
[TBL] [Abstract][Full Text] [Related]
23. Validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: extra-cranial disease progression is an independent risk factor.
Zhuang Q; Wong RX; Lian WX; Li YQ; Wong FY
Ann Palliat Med; 2019 Sep; 8(4):390-400. PubMed ID: 30943738
[TBL] [Abstract][Full Text] [Related]
24. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
25. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients.
Lagerwaard FJ; Levendag PC; Nowak PJ; Eijkenboom WM; Hanssens PE; Schmitz PI
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):795-803. PubMed ID: 10098435
[TBL] [Abstract][Full Text] [Related]
26. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].
Zhang T; Li Q; Xu B; Zhang P; Yuan P; Ma F; Wang J; Fan Y
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):697-702. PubMed ID: 25564062
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy.
Leone JP; Lee AV; Brufsky AM
Cancer Med; 2015 Jul; 4(7):989-94. PubMed ID: 25756607
[TBL] [Abstract][Full Text] [Related]
28. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
29. Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.
Rochefort P; Chabaud S; Pierga JY; Tredan O; Brain E; Bidard FC; Schiffler C; Polena H; Khalil-Mgharbel A; Vilgrain I; Bachelot T
Br J Cancer; 2017 Jan; 116(3):356-361. PubMed ID: 28056463
[TBL] [Abstract][Full Text] [Related]
30. [Predictive value of combination detection of tissue Pgp1 expression and preoperative serum CEA level for colorectal cancer].
Wu F; Chen L; Wu W; Jiang B; Su X
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):443-449. PubMed ID: 28440527
[TBL] [Abstract][Full Text] [Related]
31. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
[TBL] [Abstract][Full Text] [Related]
33. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
35. Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer.
Witzel I; Kantelhardt EJ; Milde-Langosch K; Ihnen M; Zeitz J; Harbeck N; Jänicke F; Müller V
Onkologie; 2011; 34(6):304-8. PubMed ID: 21625183
[TBL] [Abstract][Full Text] [Related]
36. Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases.
Braccini AL; Azria D; Thezenas S; Romieu G; Ferreri JM; Jacot W
BMC Cancer; 2013 Feb; 13():70. PubMed ID: 23394467
[TBL] [Abstract][Full Text] [Related]
37. Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype.
Matsunaga S; Shuto T; Kawahara N; Suenaga J; Inomori S; Fujino H
J Neurosurg; 2010 Dec; 113 Suppl():65-72. PubMed ID: 21121788
[TBL] [Abstract][Full Text] [Related]
38. Tumor marker analyses in patients with brain metastases: patterns of practice and implications for survival prediction research.
Nieder C; Dalhaug A; Haukland E; Mannsåker B; Pawinski A
Tumour Biol; 2015 Aug; 36(8):6471-6. PubMed ID: 25801247
[TBL] [Abstract][Full Text] [Related]
39. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
40. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.
Baquero MT; Hanna JA; Neumeister V; Cheng H; Molinaro AM; Harris LN; Rimm DL
Cancer; 2012 Oct; 118(19):4660-9. PubMed ID: 22359235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
